Drug Trial Radar · NCT03386942
A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
82
Actual
Start
Nov 28, 2017
Primary completion
Oct 26, 2022
Study completion Oct 26, 2022
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- First posted
- Dec 29, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the tolerability and safety profile of farletuzumab ecteribulin in participants with solid tumors.
Conditions
- Solid Tumors
Interventions
Farletuzumab EcteribulinDrug
Part 1: farletuzumab ecteribulin intravenous (IV) infusion administered every 3 weeks starting at a 0.3 mg/kg dose and successively increasing doses until DLT. Part 2: farletuzumab ecteribulin administered IV every 3 weeks at a dose determined in Part 1 until any of the criteria for discontinuation are met.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of participants with dose-limiting toxicities (DLTs)Time frame: At the end of Cycle 1 (21 days)
- Part 1 and Part 2: Number of participants with adverse events (AEs), adverse events of interest (AEIs), and serious adverse events (SAEs)Time frame: Up to 50 months
- Number of participants with any clinically significant clinical laboratory test valueTime frame: Up to 50 months
- Number of participants with any clinically significant vital sign valueTime frame: Up to 50 months
- Change from Baseline in arterial oxygen saturationTime frame: Baseline; up to 50 months
- Change from Baseline in body weightTime frame: Baseline; up to 50 months
- Number of participants with any clinically significant 12-lead electrocardiogram (ECG) valueTime frame: Up to 50 months
- Change from Baseline in the performance status (PS) score established by the Eastern Cooperative Oncology Group (ECOG)Time frame: Baseline; up to 50 months
- Change from Baseline in serum anti-drug antibody (ADA) titerTime frame: Baseline; up to 50 months
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Eisai Trial Site 5
Matsuyama, Ehime, Japan
Eisai Trial Site 6
Kurume, Fukuoka, Japan
Eisai Trial Site 8
Sapporo, Hokkaido, Japan
Eisai Trial Site 4
Akashi, Hyōgo, Japan
Eisai Trial Site 7
Niigata, Niigata, Japan
Eisai Trial Site 3
Hidaka, Saitama, Japan
Eisai Trial Site 9
Sunto-gun, Shizuoka, Japan
Eisai Trial Site 1
Chuo-ku, Tokyo, Japan
Eisai Trial Site 2
Koto-ku, Tokyo, Japan
Eisai Trial Site 10
Koto-Ku, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.